Tirzepatide in adolescent MASLD

A case series published online on 12 October 2026 describes two 18-year-olds with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) who received tirzepatide alongside lifestyle care. Both lost weight and had lower liver-enzyme measurements. Imaging markers also improved, but neither patient had a liver biopsy, the follow-up periods differed, and a two-person report cannot show that tirzepatide caused the changes^[1].

The two cases showed different time courses

The first patient was an 18-year-old woman with obesity, high triglycerides, low HDL cholesterol and liver fat seen on ultrasound. Magnetic resonance elastography (MRE), an MRI-based method that estimates liver stiffness and fat, recorded a proton density fat fraction of 31.5%. This measure estimates the proportion of liver tissue signal attributable to fat. Her liver stiffness remained in the normal range, and her family declined a liver biopsy. After lifestyle measures had not produced a sustained change, the clinical team added tirzepatide for weight management^[1].

After 13 months, her liver fat fraction fell from 31.5% to 12%, an absolute reduction of 19.5 percentage points. At 15 months, body weight was 14% lower, falling from 70.9 kg to 61.1 kg. Alanine aminotransferase (ALT), a liver enzyme that can rise with liver-cell injury, fell from 102 to 30 IU/L. Gamma-glutamyl transferase fell from 36 to 12 IU/L. The report says she had no adverse events, although that observation comes from one patient^[1].

The second patient was an 18-year-old man with obesity, insulin resistance, low HDL cholesterol and six years of raised liver enzymes. His family also declined biopsy. The team followed him with FibroScan, a non-invasive test that estimates liver fat and stiffness. After three months, body weight was 7% lower, from 97.4 kg to 90.3 kg, and ALT fell from 135 to 79 IU/L. The reported liver-stiffness measurement fell from 8.8 to 4.7 kPa. He reported mild nausea on injection days that resolved without further intervention^[1].

The report cannot establish liver benefit

These observations are clinically interesting because the weight, enzyme and imaging measurements moved in the same direction. They still leave the central question unanswered. There was no comparison group, and both patients continued lifestyle care while receiving tirzepatide. Weight loss itself can change liver fat and liver enzymes, so the report cannot separate a drug effect on liver disease from changes associated with lower body weight, diet, activity or time^[1].

Biopsy was not performed before or after treatment. The authors therefore could not confirm metabolic dysfunction-associated steatohepatitis (MASH), the inflammatory form of fatty liver disease, stage any fibrosis under a microscope or show histological improvement. They also caution that FibroScan measurements in adolescents can vary with body mass index, inflammation and technique. The three-month observation in the second case is too short to answer whether the changes persist^[1].

The word adolescent also needs context here. Both patients were 18, the threshold for adult weight-management labelling in the United States. The paper discusses them within a pediatric service and the transition to adult care, but it supplies no evidence for younger adolescents with MASLD. Its authors describe the report as the first case series of tirzepatide in adolescent MASLD and call for larger cohorts with a wider age range and longer follow-up^[1].

Adult MASH data provide a separate signal

The strongest liver-specific tirzepatide evidence comes from adults, not adolescents. A randomized phase 2 trial enrolled 190 adults with biopsy-confirmed MASH and moderate or severe fibrosis. At 52 weeks, MASH resolved without worsening fibrosis in 44%, 56% and 62% of participants assigned to 5 mg, 10 mg and 15 mg tirzepatide, respectively, compared with 10% on placebo. The trial also reported improvement of at least one fibrosis stage without worsening MASH in 51% to 55% of the tirzepatide groups and 30% of the placebo group^[2].

That trial supports testing tirzepatide in liver disease, but it does not validate the two adolescent cases. Its participants had biopsy-confirmed disease, were adults and were randomized. The case-series patients had imaging and biochemical evidence of MASLD without biopsy confirmation. Direct evidence in adolescents would need its own controlled design, age-appropriate safety monitoring and liver outcomes chosen before treatment begins.

Pediatric evidence comes from type 2 diabetes

SURPASS-PEDS supplies controlled pediatric safety and metabolic data in another condition. The trial randomized 99 participants aged 10 to under 18 with type 2 diabetes to tirzepatide or placebo. At 30 weeks, pooled tirzepatide reduced glycated hemoglobin by 2.23 percentage points while placebo increased it by 0.05 points. Body mass index fell by 7.4% in the 5 mg group and 11.2% in the 10 mg group, compared with 0.4% on placebo. The most common adverse events were mild or moderate gastrointestinal events^[3].

SURPASS-PEDS did not enroll participants for MASLD and did not test whether tirzepatide improves pediatric liver disease. It shows that tirzepatide has been studied under randomized conditions in younger people with type 2 diabetes. It cannot fill the missing controlled liver-outcome evidence identified by the case-series authors^[3].

The current label draws a firm boundary

The current US Mounjaro label includes adults and pediatric patients aged 10 years and older with type 2 diabetes. It does not list MASLD or MASH as an indication. The label identifies tirzepatide as a dual GIP and GLP-1 receptor agonist and carries a boxed warning about thyroid C-cell tumors observed in rats, with human relevance undetermined. It also describes pancreatitis, gallbladder disease, kidney injury related to dehydration and sometimes severe gastrointestinal reactions among its warnings and precautions^[4].

The case series is an early clinical observation and does not support self-directed use or a pediatric MASLD dosing protocol. Tirzepatide remains a prescription medicine whose approved uses depend on brand and jurisdiction. Our tirzepatide regulation section tracks those distinctions.

A controlled adolescent study is the next test

A useful next study would enroll adolescents with clearly defined MASLD, record baseline disease severity and compare tirzepatide with an appropriate control alongside the same lifestyle support. Prespecified outcomes could include liver fat by MRI, ALT, fibrosis measures, weight, adverse events and treatment discontinuation. Longer follow-up would show whether early changes persist and whether uncommon harms emerge. Biopsy may not be feasible for every participant, but the protocol would need enough validated liver measures to distinguish weight loss from improvement in liver disease^[1].